(ANSA) – Laboratories GlaxoSmithKline and Pfizer He decided to "joint venture" (a strategic alliance of businesses), "over-the-counter medicines" and long-term consumer products segment. The goal of the operation is to create a global giant in the healthcare sector with a turnover of $ 12,700 million. Glaxo will have a 68% share of the contract in the new entity and intends to make public the next three years.
In the second half of 2019, the agreement should be closed and, when Glaxo said, it is divided into two companies, drug and vaccines and the other in the health of consumers.
Together, last year they had sales of $ 12.7 million. Drug manufacturers once imagined that home-care medicine was monitored at every corner of the cabinet, for personal treatment for cancer and cardiovascular disease.
However, large pharmaceutical companies are increasingly based on high-priced drug development, based on advanced genetics and other advanced research. Additionally, the cost of reviewing cures increases, but insurers and governments demand lower prices.
In the meantime, the profits of many consumers' businesses have shrunk because the competition and companies like Amazon and Walmart have an increasing power. Over the past year, these pressures have led to unconventional combinations of pharmaceutical operators, health insurance companies and online commerce. At the same time, other companies that were betting on health care have come out. Finally, General Electric demanded a segregation of his health line. However, both giants want to save everything. Or maybe they already got it.